<DOC>
	<DOCNO>NCT01844401</DOCNO>
	<brief_summary>The primary objective study compare pharmacokinetic ( PK ) profile Albuterol Spiromax® ProAir HFA administration single inhale dose 180 mcg albuterol base product .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Profiles Albuterol Spiromax® ProAir® Hydrofluoroalkane ( HFA ) Pediatric Patients With Asthma</brief_title>
	<detailed_description>This single center , open-label , 2-period crossover study . The study consist screen visit follow treatment period comprise 2 treatment visit . The treatment period visit separate 4 14-day washout period . Eligible patient keep overnight prior treatment period .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Procaterol</mesh_term>
	<criteria>1 . Written inform consent/assent sign dated patient and/or parent/caregiver/legal guardian ( appropriate ) conduct studyrelated procedure . 2 . Male premenarchal female patient 411 year age , inclusive , Screening Visit ( SV ) 3 . Has document physician diagnosis persistent asthma minimum 3 month duration stable least 4 week prior SV . The asthma diagnosis must accordance National Asthma Education Prevention Program Guidelines Expert Panel Report 3 ( EPR3 ) . 4 . Forced expiratory volume 1 second ( FEV1 ) &gt; 80 % predicted age , height gender race SV base pediatric population standard . 5 . Any patient treat inhaled corticosteroid ( ICS ) must lowdose regimen ( 200 mcg less fluticasone propionate per day equivalent ) , stable least 4 week prior SV expect maintained duration study 6 . Has require less 4 inhalation per week rescue bronchodilator ( average ) 4 week precede SV 7 . Has ability withhold inhale albuterol least 72 hour precede Treatment Visit ( TV ) . Other criterion apply , include must weigh least 45 pound 1 . A known hypersensitivity albuterol excipients inhaler formulation ( lactose , ethanol , etc . ) 2 . Participation ( receive study drug ) investigational drug trial within 30 day precede SV plan participation another investigational drug trial time trial 3 . History severe milk protein allergy 4 . Proneness orthostatic dysregulation , syncope , blackouts 5 . History respiratory infection disorder ( include , limited bronchitis , pneumonia , acute chronic sinusitis , otitis medium , influenza ) resolve within 2 week precede SV . 6 . History lifethreatening asthma define protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizures 7 . Any asthma exacerbation require systemic corticosteroid within 3 month SV . A patient must hospitalization asthma within 6 month prior SV . Other criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>persistent asthma</keyword>
	<keyword>Albuterol Spiromax®</keyword>
	<keyword>ProAir® HFA</keyword>
	<keyword>Pediatric Patients</keyword>
	<keyword>Phase 1</keyword>
</DOC>